JP7640047B2 - がん細胞を特異的に攻撃しているｔ細胞を同定するための特異的マーカー - Google Patents

がん細胞を特異的に攻撃しているｔ細胞を同定するための特異的マーカー Download PDF

Info

Publication number
JP7640047B2
JP7640047B2 JP2021530728A JP2021530728A JP7640047B2 JP 7640047 B2 JP7640047 B2 JP 7640047B2 JP 2021530728 A JP2021530728 A JP 2021530728A JP 2021530728 A JP2021530728 A JP 2021530728A JP 7640047 B2 JP7640047 B2 JP 7640047B2
Authority
JP
Japan
Prior art keywords
cell
cells
tcr
subpopulation
cell subpopulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021530728A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021006316A1 (https=
Inventor
庸介 冨樫
博嘉 西川
和男 山下
ニコラ クロード ポール サックス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Cancer Center Japan
Original Assignee
National Cancer Center Japan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Cancer Center Japan filed Critical National Cancer Center Japan
Publication of JPWO2021006316A1 publication Critical patent/JPWO2021006316A1/ja
Application granted granted Critical
Publication of JP7640047B2 publication Critical patent/JP7640047B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2021530728A 2019-07-10 2020-07-09 がん細胞を特異的に攻撃しているｔ細胞を同定するための特異的マーカー Active JP7640047B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019128517 2019-07-10
JP2019128517 2019-07-10
PCT/JP2020/026897 WO2021006316A1 (ja) 2019-07-10 2020-07-09 がん細胞を特異的に攻撃しているｔ細胞を同定するための特異的マーカー

Publications (2)

Publication Number Publication Date
JPWO2021006316A1 JPWO2021006316A1 (https=) 2021-01-14
JP7640047B2 true JP7640047B2 (ja) 2025-03-05

Family

ID=74114521

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021530728A Active JP7640047B2 (ja) 2019-07-10 2020-07-09 がん細胞を特異的に攻撃しているｔ細胞を同定するための特異的マーカー

Country Status (5)

Country Link
US (1) US20220257656A1 (https=)
EP (1) EP3998082A4 (https=)
JP (1) JP7640047B2 (https=)
CN (1) CN114080231B (https=)
WO (1) WO2021006316A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240052309A1 (en) * 2021-01-04 2024-02-15 Thyas Co. Ltd. Method for producing regenerated t cell via ips cell
WO2025141875A1 (ja) * 2023-12-28 2025-07-03 国立大学法人三重大学 腫瘍反応性ｔ細胞の製造方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018182817A1 (en) 2017-03-29 2018-10-04 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
JP2018533364A (ja) 2015-10-30 2018-11-15 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 幹細胞からｔ細胞を作製する方法および該ｔ細胞を用いた免疫療法的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58168464A (ja) 1982-03-30 1983-10-04 Kobe Steel Ltd 類似鋼種の多連連続鋳造法
EP2203746B1 (en) * 2007-09-24 2013-03-06 Technion Research & Development Foundation Ltd. T cell subpopulations capable of treating cancer
CN102539736B (zh) * 2011-12-16 2015-04-29 北京汉氏联合生物技术有限公司 一种cd106阳性细胞、其鉴定、制备方法及应用
EP2961415B1 (en) * 2013-03-01 2021-01-06 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods of producing enriched populations of tumor-reactive t cells from tumor
ES2946697T3 (es) * 2014-09-10 2023-07-24 Miltenyi Biotec Bv & Co Kg Una población celular para su uso en el tratamiento de cáncer
ES3000510T3 (en) * 2017-06-09 2025-02-28 Providence Health & Services Oregon Tumor-infiltrating t-cells for use in the treatment of cancer
EP3701041A4 (en) * 2017-10-27 2021-11-17 The Trustees of The University of Pennsylvania METHODS AND COMPOSITIONS FOR TREATMENT OF DISEASES ASSOCIATED WITH EXHAUSTED T-CELLS
CN109777872B (zh) * 2017-11-15 2021-04-02 北京大学 肺癌中的t细胞亚群及其特征基因
JP2019128517A (ja) 2018-01-26 2019-08-01 ソニーセミコンダクタソリューションズ株式会社 撮像装置、及び、電子機器
CA3171559A1 (en) * 2020-03-20 2021-09-23 Sri Krishna Methods of isolating t-cells and t-cell receptors from tumor by single-cell analysis for immunotherapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018533364A (ja) 2015-10-30 2018-11-15 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 幹細胞からｔ細胞を作製する方法および該ｔ細胞を用いた免疫療法的方法
WO2018182817A1 (en) 2017-03-29 2018-10-04 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

Also Published As

Publication number Publication date
EP3998082A1 (en) 2022-05-18
CN114080231B (zh) 2025-02-14
WO2021006316A1 (ja) 2021-01-14
CN114080231A (zh) 2022-02-22
EP3998082A4 (en) 2024-02-07
US20220257656A1 (en) 2022-08-18
JPWO2021006316A1 (https=) 2021-01-14

Similar Documents

Publication Publication Date Title
Freeman et al. A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target
Duraiswamy et al. Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation
Pereira et al. Sestrins induce natural killer function in senescent-like CD8+ T cells
Xu et al. Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer
Li et al. Co-inhibitory molecule B7 superfamily member 1 expressed by tumor-infiltrating myeloid cells induces dysfunction of anti-tumor CD8+ T cells
Harlin et al. Tumor progression despite massive influx of activated CD8+ T cells in a patient with malignant melanoma ascites
Lowther et al. PD-1 marks dysfunctional regulatory T cells in malignant gliomas
US20210017493A1 (en) Method of enhancing persistence of adoptively infused t cells
Borgers et al. Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial
JP7760374B2 (ja) Ｔ細胞治療薬を生成するためのエクスビボ方法ならびに関連する組成物および方法
Zhang et al. Single-cell sequencing reveals antitumor characteristics of intratumoral immune cells in old mice
TWI786096B (zh) 癌症免疫療法之新穎生物標記
Fozza et al. Azacitidine improves the T-cell repertoire in patients with myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia
Collier et al. Single-cell profiling reveals unique features of diabetogenic T cells in anti-PD-1-induced type 1 diabetes mice
Shah et al. Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes
CN113710274A (zh) 用于预测癌症免疫疗法中的长期存活的方法及组合物
Mensink et al. Tregs from human blood differentiate into nonlymphoid tissue–resident effector cells upon TNFR2 costimulation
Davies et al. Non-synergy of PD-1 blockade with T-cell therapy in solid tumors
Chambers et al. Functional expression of CD73 on human natural killer cells
JP7640047B2 (ja) がん細胞を特異的に攻撃しているｔ細胞を同定するための特異的マーカー
Stromnes et al. Insufficiency of compound immune checkpoint blockade to overcome engineered T cell exhaustion in pancreatic cancer
Ibáñez-Molero et al. Tumour-reactive heterotypic CD8 T cell clusters from clinical samples
Campos-Mora et al. NK cells in peripheral blood carry trogocytosed tumor antigens from solid cancer cells
US20250332198A1 (en) Targeted elimination of senescent cells by gamma-delta t cells
Nong et al. Circulating CD137+ CD8+ T cells accumulate along with increased functional regulatory T cells and thoracic tumour burden in lung cancer patients

Legal Events

Date Code Title Description
AA64 Notification of invalidation of claim of internal priority (with term)

Free format text: JAPANESE INTERMEDIATE CODE: A241764

Effective date: 20220331

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240304

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240920

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241015

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250206

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250212

R150 Certificate of patent or registration of utility model

Ref document number: 7640047

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150